Yourlawyer.com (Campath News) http://www.yourlawyer.com/topics/overview/Campath Sat, 21 Nov 2009 18:15:33 -0800 pixel-app en US FDA issues warning on Schering's MS drug Campath http://www.yourlawyer.com/articles/read/10994 Thu, 01 Dec 2005 00:00:00 -0800 http://www.yourlawyer.com/articles/read/10994 The US Food and Drug Administration has issued a warning on the use of Schering AG's multiple sclerosis drug Campath.

The FDA said three patients in a clinical study on the drug developed severe idiopathic thrombocytopenic purpura (ITP), a rare autoimmune disorder characterised by an acute shortage of platelets with resultant bruising and spontaneous bleeding.

One of the patients died, the FDA said.

Campath is so far not approved to treat MS. It is only approved for treating a form of blood cancer called B-cell chronic lymphocytic leukemia (B-CLL).

The label for Campath has a warning about serious and rare blood problems that may occur with the use of this medicine.

Schering could not be reached for comment.
]]> http://www.yourlawyer.com/topics/overview/Campath Thu, 01 Dec 2005 00:00:00 -0800 http://www.yourlawyer.com/topics/overview/Campath DOWNLOAD OUR CAMPATH INFORMATION PACKAGE

Injured by Campath?

Campath manufactured by Schering and Genzyme Corp. is approved to treat Leukemia. The FDA, on May 7, 2001 approved Campath. On September 16, 2005 Genzyme and Schering suspended dosages in a trial study for Campath after reports of three cases of serious side effects that lead to a death. The Phase II or mid-stage trial side effects consisted of three cases of Idiopathic Thrombocytopenic Purpura (ITP).

Idiopathic Thrombocytopenic Purpura (ITP) is a condition in which patients experience a low platelet count that can cause abnormal bleeding. Genzyme and Schering said they have notified regulatory authorities, trial sites and patients about risks. The companies have consulted a panel of experts to advise the companies on how to reduce risks of ITP.

Treatments for Multiple Sclerosis have recently been under the microscope after the drug Tysabri, made by Elan Corp. and Biogen Idec Inc. was removed from the market in February after it was linked to a rare and potentially fatal brain disease.

If you or a loved one took Campath and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.]]>